Besides the respiratory system, other organs have been shown to be affected by severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) infection, such as the gastrointestinal tract,[^1^](#cts12862-bib-0001){ref-type="ref"} the liver,[^2^](#cts12862-bib-0002){ref-type="ref"} and the kidneys.[^3^](#cts12862-bib-0003){ref-type="ref"} Renal impairment has been observed by several studies as a major secondary outcome of coronavirus disease 2019 (COVID‐19) infection, following respiratory dysfunction.[^4^](#cts12862-bib-0004){ref-type="ref"} Acute kidney injury during COVID‐19 infection could be due to several factors, including the direct infection of renal cells with SARS‐CoV‐2, cytokine storm, inflammation, and drug‐induced toxicity. The progression of renal injury needs to be correlated clinically with the course of COVID‐19 to further understand its underlying mechanisms. In a recent observation by Cheng and colleagues,[^3^](#cts12862-bib-0003){ref-type="ref"} renal impairment on admission correlated with poor outcomes among patients with COVID‐19. The level of renal impairment and elevated baseline serum creatinine were associated with a more severe course of SARS‐CoV‐2 infection, and with higher likelihood of intensive care unit admission, and mechanical ventilation. This reported increase in serum creatinine early during the infection suggests that it could be attributed to early infection of the kidneys by SARS‐CoV‐2. On the other hand, late impairments could be a manifestation of systemic inflammation and multi‐organ failure or secondary to late infection of the kidneys.

Both SARS‐CoV‐1[^5^](#cts12862-bib-0005){ref-type="ref"} and SARS‐CoV‐2[^2^](#cts12862-bib-0002){ref-type="ref"} were detected in urine samples. Angiotensin‐converting enzyme 2 (ACE2) is the main receptor of SARS‐CoV‐1 and 2, whereas the transmembrane serine protease, TMPRSS2, is needed to prime the viral spike protein, an essential step for virus binding to ACE2[^6^](#cts12862-bib-0006){ref-type="ref"} but the binding affinity of SARS‐CoV‐2 spike protein to ACE2 is much higher than that of SARS‐CoV‐1.[^7^](#cts12862-bib-0007){ref-type="ref"} CD147 has also been described as an alternative receptor of SARS‐CoV‐2 entry to the cell.[^8^](#cts12862-bib-0008){ref-type="ref"}

ACE2 was previously shown to be strongly expressed in kidney tubules.[^9^](#cts12862-bib-0009){ref-type="ref"} Recently, Monteil and colleagues found that SARS‐CoV‐2 can directly infect human tubular kidney cells and has the ability to replicate in the kidney organoid postinfection.[^10^](#cts12862-bib-0010){ref-type="ref"} They further demonstrated that treatment of kidney organoid with human recombinant soluble ACE2 significantly reduced SARS‐CoV‐2 infection in a dose‐dependent manner.[^10^](#cts12862-bib-0010){ref-type="ref"} By binding to SARS‐COV‐2 spike protein, the recombinant ACE2 is expected to neutralize the viral particles and prevent them from binding to cell surface receptors, and hence lowers infectivity and viral load. That said, the levels of ACE2 expression in the kidney tissues could influence renal susceptibility to SARS‐CoV‐2 infection. In this study, we set to examine the effect of commonly used medications on the expression of ACE2, TMPRSS2, and CD147 in kidney tissues. By applying bioinformatic analyses of publicly available data, we have determined the ability of 59 commonly used medications to regulate the expression of SARS‐CoV‐2 receptors in kidney tissues.

METHODS {#cts12862-sec-0002}
=======

Bioinformatic analyses were conducted to evaluate the effect of different groups of medications on mRNA expression levels of ACE2, TMPRSS2, and CD147 gene signatures in rat kidney tissues. Publicly available gene expression datasets on Open Toxicogenomic Project‐Genomics Assisted Toxicity Evaluation System[^11^](#cts12862-bib-0011){ref-type="ref"} and DrugMatrix toxicogenomic database were used. In these two toxicogenomic projects, rats were treated with different medication groups in biological triplicates for different time points. For the purpose of this study, we selected the longest exposure time available for each medication. From the Toxicogenomic Project‐Genomics Assisted Toxicity Evaluation System study, we used the data of *in vivo* daily treatments with moderate and high doses for a duration of 29 days. From the DrugMatrix database, we had chosen the daily *in vivo* treatments that were mainly administered in a single dose manner with the longest post‐treatment time points ranging from 1 day to 7 days. Hybridization to the whole genome was performed for all included samples using the RG230_2.0 rat GeneChip (Affymetrix, CA).

Before data preprocessing, all mRNA expression data were evaluated for quality control, and all poor‐quality data were removed. The raw Affymetrix data were normalized and log transformed. Microarray data (CEL files) were preprocessed with the Robust Multi‐Array Average technique using R software.[^12^](#cts12862-bib-0012){ref-type="ref"} Log‐transformed normalized intensities were used in the final analyses; and differentially expressed genes between treated and control samples were carried out using Linear Models for MicroArray data (LIMMA) analyses.[^13^](#cts12862-bib-0013){ref-type="ref"}, [^14^](#cts12862-bib-0014){ref-type="ref"} Statistical analysis was performed using R (version 3.0.2) and Prism (version 8; GraphPad Software) softwares. For all analyses, *P* values \< 0.05 were considered significant.

RESULTS AND DISCUSSION {#cts12862-sec-0003}
======================

In this study, bioinformatic analyses of publicly available drug databases were conducted to evaluate the effect of commonly used medications on kidney tissue expression of SARS‐CoV‐2 receptors (**Figure** [**1**](#cts12862-fig-0001){ref-type="fig"}). Kidney tissue is known to express ACE2 at higher levels and TMPRSS2 and CD147 at comparable levels to bronchial lung tissue (**Figure** [**1a**](#cts12862-fig-0001){ref-type="fig"}). Among the viral entry genes, renal expression of ACE2 was affected with a larger number of medications and to a greater extent. Of 59 tested medications, 56% affected ACE2 (15% increased and 41% decreased expression), 27% affected CD147 (19% increased and 8% decreased expression), whereas 24% affected TMPRSS2 (16% increased and 8% decreased expression).

![Effect of common medications on the expression levels of severe acute respiratory syndrome‐coronavirus 2 entry receptors in kidney. (**a**) Shows the baseline expression of angiotensin‐converting enzyme (ACE)2 and TMPRSS2 in healthy lung and kidney tissues extracted from the Genotype‐Tissue Expression project. (**b**) Represents the main medication classes that affected the expression levels of ACE2. (**c--e**) Shows medications causing the highest and lowest fold change for ACE2 TMPRSS2, and CD147 expression levels.](CTS-9999-na-g001){#cts12862-fig-0001}

Besides acting as the main receptor for SARS‐CoV‐1 and SARS‐CoV‐2, ACE2 enzyme plays an essential role in protecting multiple organs against injury, including the lungs,[^15^](#cts12862-bib-0015){ref-type="ref"} the heart,[^16^](#cts12862-bib-0016){ref-type="ref"} and the kidneys.[^17^](#cts12862-bib-0017){ref-type="ref"} Therefore, although upregulation of ACE2 may increase susceptibility to COVID‐19 infection in the early phase of the disease, its suppression could lead to an extensive acute kidney injury at later stages.[^17^](#cts12862-bib-0017){ref-type="ref"} In our study, ACE2 was increased with some of the tested medication groups, namely the renin‐angiotensin inhibitors, such as enalapril, antibacterial agents, such as nitrofurantoin, and proton pump inhibitor medication, including omeprazole. The majority of the other medications decreased ACE2 expression to variable degrees. The most pronounced downregulation was observed with allopurinol (gout medication) and cisplatin (antineoplastic agent; **Figure** [**1b,c**](#cts12862-fig-0001){ref-type="fig"}). The average ACE2 fold change caused by each medication class was calculated and displayed in **Figure** [**1b**](#cts12862-fig-0001){ref-type="fig"}. Interestingly, among the tested analgesics, acetaminophen did not change the ACE2 expression level; whereas multiple nonsteroidal anti‐inflammatory drug medications, such as indomethacin and ibuprofen, significantly lowered the mRNA levels of this gene.

The expression level of TMPRSS2 was increased with a number of medications, such as diclofenac, furosemide, and dexamethasone (**Figure** [**1d**](#cts12862-fig-0001){ref-type="fig"}). Other medications, such as allopurinol, cisplatin, and acetaminophen, downregulated this membrane‐associated enzyme. To our knowledge, this effect of commonly used medications on the renal expression of TMPRSS2 was not reported before. The observed increase in expression of TMPRSS2 will lead to an increase in priming of the virus spike protein and, hence, may enhance the level of SARS‐CoV‐2 infectivity within this tissue.[^18^](#cts12862-bib-0018){ref-type="ref"}

We have also tested the effect of these medications on CD147 (Basigin).[^19^](#cts12862-bib-0019){ref-type="ref"} Furosemide, piroxicam, prednisolone, and norfloxacin were among the top upregulating medications for CD147 expression, whereas cisplatin, sulindac, and nimesulide were among the top suppressors of its expression (**Figure** [**1e**](#cts12862-fig-0001){ref-type="fig"}). The regulatory effect of all the different medications on the expression of SARS‐CoV‐2 receptors is presented in **Table** [**1**](#cts12862-tbl-0001){ref-type="table"}.

###### 

Effect of common medications treatments on expression levels of renal SARS‐Cov‐2 receptors of *ACE2 and TMPRSS2*

  Medication                                          Classifications                                     Repeat dose mg/kg                                                          ACE2 mRNA fold change (*P* value)                                          TMPRSS2 mRNA fold change (*P* value)                                       BSG (CD147) mRNA fold change (*P* value)
  --------------------------------------------------- --------------------------------------------------- -------------------------------------------------------------------------- -------------------------------------------------------------------------- -------------------------------------------------------------------------- ----------------------------------------------------------------------
  Acetaminophen, 29 days, oral                        Analgesics                                          600                                                                        Nonsignificant                                                             **−0.26 (*P *= 0.002)** [\*\*](#cts12862-note-1200){ref-type="fn"}         Nonsignificant
  Analgesics                                          1,000                                               Nonsignificant                                                             Nonsignificant                                                             Nonsignificant                                                             
  Captopril, 29 days, oral                            Renin‐angiotensin system inhibitors                 100                                                                        Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Renin‐angiotensin system inhibitors                 300                                                 **0.23 (*P *= 0.045)** [\*](#cts12862-note-1100){ref-type="fn"}            Nonsignificant                                                             Nonsignificant                                                             
  Renin‐angiotensin system inhibitors                 1,000                                               Nonsignificant                                                             Nonsignificant                                                             Nonsignificant                                                             
  Captopril, 5 days, oral                             Renin‐angiotensin system inhibitors                 1,750                                                                      Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Candesartan, 3 days, oral                           Renin‐angiotensin system inhibitors                 1,300                                                                      **0.25 (*P *= 0.021)** [\*](#cts12862-note-1100){ref-type="fn"}            Nonsignificant                                                             Nonsignificant
  Enalapril, 29 days, oral                            Renin‐angiotensin system inhibitors                 300                                                                        Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Renin‐angiotensin system inhibitors                 600                                                 **0.54 (*P *\< 0.0001)** [\*\*\*\*](#cts12862-note-1400){ref-type="fn"}    Nonsignificant                                                             Nonsignificant                                                             
  Ramipril, 3 days, oral                              Renin‐angiotensin system inhibitors                 1,500                                                                      Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Spironolactone, 5 days                              Diuretics                                           300                                                                        Nonsignificant                                                             Nonsignificant                                                             **0.27 (*P *= 0.002)** [\*\*](#cts12862-note-1200){ref-type="fn"}
  Triamterene, 29 days, oral                          Diuretics                                           50                                                                         Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Diuretics                                           150                                                 **−0.47 (*P *= 0.002)** [\*\*](#cts12862-note-1200){ref-type="fn"}         Nonsignificant                                                             Nonsignificant                                                             
  Furosemide, 5 days, oral                            Diuretics                                           375                                                                        **−0.68 (*P *= 0.006)** [\*\*](#cts12862-note-1200){ref-type="fn"}         **0.27 (*P *= 0.01)** [\*](#cts12862-note-1100){ref-type="fn"}             **0.53 (*P *= 0.0001)** [\*\*\*](#cts12862-note-1300){ref-type="fn"}
  Diclofenac, 5 days, oral                            Analgesics › nonsteroidal anti‐inflammatory drugs   3.5                                                                        Nonsignificant                                                             **0.59 (*P *= 0.0003)** [\*\*\*](#cts12862-note-1300){ref-type="fn"}       Nonsignificant
  Ibuprofen, 5 days, oral                             Analgesics › nonsteroidal anti‐inflammatory drugs   263                                                                        **−1.15 (*P *= 0.048)** [\*\*](#cts12862-note-1200){ref-type="fn"}         Nonsignificant                                                             Nonsignificant
  Indomethacin, 29 days, oral                         Analgesics › nonsteroidal anti‐inflammatory drugs   1.6                                                                        Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Analgesics › nonsteroidal anti‐inflammatory drugs   5                                                   **−1.39 (*P *= 0.048)** [\*\*](#cts12862-note-1200){ref-type="fn"}         Nonsignificant                                                             Nonsignificant                                                             
  Mefenamic acid, 5 days, oral                        Analgesics › nonsteroidal anti‐inflammatory drugs   93                                                                         Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Meloxicam, 1 day, oral                              Analgesics › nonsteroidal anti‐inflammatory drugs   33                                                                         **−0.52 (*P *= 0.0009)** [\*\*\*](#cts12862-note-1300){ref-type="fn"}      **−0.32 (*P *= 0.006)** [\*\*](#cts12862-note-1200){ref-type="fn"}         Nonsignificant
  Piroxicam, 5 days, oral                             Analgesics › nonsteroidal anti‐inflammatory drugs   14                                                                         **−0.52 (*P *= 0.01)** [\*](#cts12862-note-1100){ref-type="fn"}            Nonsignificant                                                             **0.33 (*P *= 0.0008)**
  Naproxen, 1 day, oral                               Analgesics › nonsteroidal anti‐inflammatory drugs   134                                                                        **−0.75 (*P *= 0.002)** [\*\*](#cts12862-note-1200){ref-type="fn"}         **0.19 (*P *= 0.022)** [\*](#cts12862-note-1100){ref-type="fn"}            Nonsignificant
  Nimesulide, 5 days, oral                            Analgesics › nonsteroidal anti‐inflammatory drugs   162                                                                        **−0.86 (*P *= 0.02)** [\*\*](#cts12862-note-1200){ref-type="fn"}          Nonsignificant                                                             **−0.41 (*P *= 0.001)** [\*\*](#cts12862-note-1200){ref-type="fn"}
  Sulindac, 1 day, oral                               Analgesics › nonsteroidal anti‐inflammatory drugs   23                                                                         Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Analgesics › nonsteroidal anti‐inflammatory drugs   64                                                  Nonsignificant                                                             Nonsignificant                                                             **−0.43 (*P *= 0.002)** [\*\*](#cts12862-note-1200){ref-type="fn"}         
  Rofecoxib, 1 day, oral                              Selective nonsteroidal anti‐inflammatory drugs      755                                                                        Nonsignificant                                                             **0.23 (*P *= 0.006)** [\*\*](#cts12862-note-1200){ref-type="fn"}          Nonsignificant
  Dexamethasone, 3 days, oral                         Corticosteroids                                     300                                                                        **−0.50 (*P *= 0.022)** [\*](#cts12862-note-1100){ref-type="fn"}           **0.26 (*P *= 0.013)** [\*](#cts12862-note-1100){ref-type="fn"}            **0.17 (*P *= 0.032)** [\*](#cts12862-note-1100){ref-type="fn"}
  Hydrocortisone, 5 days, s.c.                        Corticosteroids                                     65                                                                         **−0.94 (*P *= 0.002)** [\*\*](#cts12862-note-1200){ref-type="fn"}         Nonsignificant                                                             Nonsignificant
  Prednisolone, 1 day, oral                           Corticosteroids                                     184                                                                        **−0.61 (*P *\< 0.0001)** [\*\*\*\*](#cts12862-note-1400){ref-type="fn"}   Nonsignificant                                                             **0.33 (*P *= 0.005)** [\*\*](#cts12862-note-1200){ref-type="fn"}
  Methyltestosterone, 29 days, oral                   Androgens                                           100                                                                        **0.42 (*P *= 0.0007)** [\*\*\*](#cts12862-note-1300){ref-type="fn"}       Nonsignificant                                                             Nonsignificant
  Androgens                                           300                                                 **0.37 (*P *= 0.006)** [\*\*](#cts12862-note-1200){ref-type="fn"}          Nonsignificant                                                             Nonsignificant                                                             
  Ethinylestradiol, 29 days, oral                     Contraceptives                                      3                                                                          Nonsignificant                                                             **0.33 (*P *= 0.0004)** [\*\*\*](#cts12862-note-1300){ref-type="fn"}       **−0.18 (*P *= 0.03)** [\*](#cts12862-note-1100){ref-type="fn"}
  Contraceptives                                      10                                                  Nonsignificant                                                             **0.32 (*P *= 0.002)** [\*\*](#cts12862-note-1200){ref-type="fn"}          Nonsignificant                                                             
  Omeprazole, 29 days, oral                           Proton pump inhibitors                              300                                                                        **0.52 (*P *= 0.001)** [\*\*](#cts12862-note-1200){ref-type="fn"}          Nonsignificant                                                             Nonsignificant
  Proton pump inhibitors                              1,000                                               Nonsignificant                                                             Nonsignificant                                                             Nonsignificant                                                             
  Penciclovir, 5 days, s.c.                           Antiviral                                           1,200                                                                      **−1.21 (*P *= 0.013)** [\*](#cts12862-note-1100){ref-type="fn"}           Nonsignificant                                                             Nonsignificant
  Saquinavir_1d_Oral                                  Antiviral                                           1,200                                                                      **−0.44 (*P *= 0.0002)** [\*](#cts12862-note-1100){ref-type="fn"}          Nonsignificant                                                             Nonsignificant
  Ritonavir, 1 d, Oral                                Antiviral                                           1,200                                                                      Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Gentamicin, 29d, oral                               Antibacterials                                      30, 100                                                                    Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Vancomycin, 5 days, i.v.                            Antibacterials                                      160                                                                        **−0.81 (*P *= 0.002)** [\*\*](#cts12862-note-1200){ref-type="fn"}         Nonsignificant                                                             Nonsignificant
  Amikacin, 5 days, i.p.                              Antibacterials                                      160                                                                        Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Ciprofloxacin, 29 days, oral                        Antibacterials                                      300                                                                        **0.34 (*P *= 0.008)** [\*\*](#cts12862-note-1200){ref-type="fn"}          Nonsignificant                                                             Nonsignificant
  Antibacterials                                      1,000                                               **0.24 (*P *= 0.04)** [\*](#cts12862-note-1100){ref-type="fn"}             Nonsignificant                                                             Nonsignificant                                                             
  Norfloxacin, 5 days, oral                           Antibacterials                                      1,500                                                                      **−0.5 (*P *= 0.004)** [\*\*](#cts12862-note-1200){ref-type="fn"}          **0.26 (*P *= 0.007)** [\*\*](#cts12862-note-1200){ref-type="fn"}          **0.33 (*P *= 0.0007)** [\*\*\*](#cts12862-note-1300){ref-type="fn"}
  Cephalexin, 3 days, oral                            Antibacterials                                      2,500                                                                      Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Azithromycin, 5 days                                Antibacterials                                      225                                                                        **0.23 (*P *= 0.04)** [\*](#cts12862-note-1100){ref-type="fn"}             Nonsignificant                                                             Nonsignificant
  Erythromycin ethylsuccinate, 29 days, oral          Antibacterials                                      300                                                                        Nonsignificant                                                             Nonsignificant                                                             **0.11 (*P *= 0.024)** [\*](#cts12862-note-1100){ref-type="fn"}
  Antibacterials                                      1,000                                               Nonsignificant                                                             Nonsignificant                                                             **0.2 (*P *= 0.003)** [\*\*](#cts12862-note-1200){ref-type="fn"}           
  Nitrofurantoin, 29 days, oral                       Antibacterials                                      30                                                                         Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Antibacterials                                      100                                                 **0.6 (*P *= 0.02)** [\*](#cts12862-note-1100){ref-type="fn"}              Nonsignificant                                                             Nonsignificant                                                             
  Ketoconazole, 29 days, oral                         Antifungals                                         30                                                                         Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Antifungals                                         100                                                 Nonsignificant                                                             Nonsignificant                                                             **0.15 (*P *= 0.04)** [\*](#cts12862-note-1100){ref-type="fn"}             
  Ethambutol, 3 days, oral                            Antimycobacterials                                  998                                                                        Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Rifampicin, 29 days, oral                           Antimycobacterials                                  60, 200                                                                    Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Cyclophosphamide, 29 days, oral                     Antineoplastic drugs                                5, 15                                                                      Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Cisplatin, 29 days, oral                            Antineoplastic drugs                                0.1                                                                        Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Antineoplastic drugs                                0.3                                                 **−0.83 (*P *= 0.0005)** [\*\*\*](#cts12862-note-1300){ref-type="fn"}      Nonsignificant                                                             Nonsignificant                                                             
  Antineoplastic drugs                                1                                                   **−2.87 (*P *\< 0.0001)** [\*\*\*\*](#cts12862-note-1400){ref-type="fn"}   **−0.53 (*P *\< 0.0001)** [\*\*\*\*](#cts12862-note-1400){ref-type="fn"}   **−0.53 (*P *\< 0.0001)** [\*\*\*\*](#cts12862-note-1400){ref-type="fn"}   
  Lomustine, 29 days, oral                            Antineoplastic drugs                                2                                                                          Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Antineoplastic drugs                                6                                                   **−0.94 (*P *\< 0.0001)** [\*\*\*\*](#cts12862-note-1400){ref-type="fn"}   Nonsignificant                                                             Nonsignificant                                                             
  Doxorubicin, 29 days, oral                          Antineoplastic drugs                                0.3                                                                        Nonsignificant                                                             −0.13(*P *= 0.038)[\*](#cts12862-note-1100){ref-type="fn"}                 Nonsignificant
  Antineoplastic drugs                                1                                                   **−0.88 (*P *= 0.026)** [\*\*\*](#cts12862-note-1300){ref-type="fn"}       Nonsignificant                                                             Nonsignificant                                                             
  Imipramine, 29 days, oral                           Antidepressants                                     30                                                                         **−0.30 (*P *= 0.002)** [\*\*](#cts12862-note-1200){ref-type="fn"}         Nonsignificant                                                             Nonsignificant
  Antidepressants                                     100                                                 Nonsignificant                                                             0.26 (*P *= 0.009)[\*\*](#cts12862-note-1200){ref-type="fn"}               Nonsignificant                                                             
  Amitriptyline, 1 day, oral                          Antidepressants                                     160                                                                        Nonsignificant                                                             Nonsignificant                                                             **0.28 (*P *= 0.04)** [\*\*](#cts12862-note-1200){ref-type="fn"}
  Valproic acid, 29 days, oral                        Antiepileptics                                      150                                                                        Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Antiepileptics                                      450                                                 **−0.3 (*P *= 0.042)** [\*\*](#cts12862-note-1200){ref-type="fn"}          Nonsignificant                                                             Nonsignificant                                                             
  Allopurinol, 29 days, oral                          Antigout                                            50                                                                         Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Antigout                                            150                                                 **−3 (*P *\< 0.0001)** [\*\*\*\*](#cts12862-note-1400){ref-type="fn"}      **−0.78 (*P *= 0.004)** [\*\*](#cts12862-note-1200){ref-type="fn"}         **−0.38 (*P *= 0.018)** [\*](#cts12862-note-1100){ref-type="fn"}           
  Azathioprine, 5 days, oral                          Immunosuppressants                                  54                                                                         **−0.57 (*P *= 0.003)** [\*\*](#cts12862-note-1200){ref-type="fn"}         Nonsignificant                                                             Nonsignificant
  Methotrexate, 3 days, oral                          Immunosuppressants                                  27                                                                         Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Tacrolimus, 5 days, oral                            Immunosuppressants                                  134                                                                        **−0.84 (*P *\< 0.0001)** [\*\*\*\*](#cts12862-note-1400){ref-type="fn"}   Nonsignificant                                                             Nonsignificant
  Cyclosporin, 29 days, oral                          Immunosuppressants                                  30, 100                                                                    Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Aspirin, 1 day, oral                                Antiplatelet drugs                                  375                                                                        Nonsignificant                                                             Nonsignificant                                                             **0.26 (*P *= 0.01)** [\*](#cts12862-note-1100){ref-type="fn"}
  Amiodarone, 5 days, oral                            Antiarrhythmics                                     147                                                                        Nonsignificant                                                             Nonsignificant                                                             **0.3 (*P *= 0.006)** [\*](#cts12862-note-1100){ref-type="fn"}
  Fenofibrate, 5 days, oral                           Lipid modifying drugs                               215                                                                        Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Gemfibrozil, 7 days, oral                           Lipid modifying drugs                               700                                                                        Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Clofibrate, 29 days, oral                           Lipid modifying drugs                               100, 300                                                                   Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Atorvastatin, 3 days, oral                          Lipid modifying drugs                               300                                                                        Nonsignificant                                                             Nonsignificant                                                             Nonsignificant
  Calcitriol, 5 days, oral                            Supplement                                          0.04                                                                       **−0.47 (*P *= 0.009)** [\*\*](#cts12862-note-1200){ref-type="fn"}         Nonsignificant                                                             Nonsignificant

Effect of medications on expression of ACE2 and TMPRSS2 was measured with two controls vs. two treatments per dose.For all analyses, p \<0.05 was considered significant, presented as bold value. \* P\<0.05, \*\* P\<0.01, \*\*\* P\<0.001, \*\*\*\* P\<0.0001.

ACE2, angiotensin‐converting enzyme; BSG, Basigin; SARS‐CoV‐2, severe acute respiratory syndrome‐coronavirus 2.

For all analyses, *P* \<0.05 was considered significant, presented as bold value.

*P*\<0.05;

*P*\<0.01;

*P*\<0.001;

*P*\<0.0001.

John Wiley & Sons, Ltd

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

Treatment of common comorbidities, such as hypertension, often requires the chronic use of multiple medications; which may result in an additive regulatory effect on the expression of ACE2 and TMPRSS2.

Given the fact that SARS‐CoV‐2 infection does not increase the expression of ACE2 and TMPRSS2,[^6^](#cts12862-bib-0006){ref-type="ref"}, [^20^](#cts12862-bib-0020){ref-type="ref"}, [^21^](#cts12862-bib-0021){ref-type="ref"} the combined effect of these chronically used medications may modulate the susceptibility of kidney tissue to SARS‐CoV‐2 infection. For example, captopril and omeprazole, if used in combination, both increase ACE2 levels. Furosemide increases TMPRSS2 expression, despite lowering the ACE2 level, which may enhance viral priming. On the other hand, a single or combined treatment with penciclovir and acetaminophen, both of which lowers expression of entry receptors, is expected to decrease the availability of receptors for SARS‐CoV‐2 entry to the cells. Nonetheless, ACE2 plays a protective role against lung and kidney injury[^22^](#cts12862-bib-0022){ref-type="ref"}, [^23^](#cts12862-bib-0023){ref-type="ref"} and, therefore, the net biological effects of the single or combination drug therapy on the expression of these receptors is still to be elucidated.

Data presented here provides evidence that medications may regulate the expression of SARS‐CoV‐2 receptors in the kidney tissues and hence may modulate the susceptibility of the kidneys to SASR‐CoV‐2 infection. The mechanisms regulating drug‐induced receptor expression are unknown and requires further investigations. Previous *in vitro* studies of gene expression changes in response to drugs like cisplatin and ochratoxin A in rat and human kidney cell lines and rat kidney tissue slices mirror the observed *in vivo* gene expression changes in rats.[^24^](#cts12862-bib-0024){ref-type="ref"}, [^25^](#cts12862-bib-0025){ref-type="ref"}, [^26^](#cts12862-bib-0026){ref-type="ref"} However, this does not provide proof that those *in vivo* drug‐induced expression changes of SARS‐CoV‐2 receptors we observed in this bioinformatics‐based study would reflect similar changes in humans. Moreover, our results are based on public gene expression datasets and thus they may or may not reflect changes in protein expression. Therefore, confirmatory experiments at the mRNA and protein levels are needed to support our findings. Additionally, population studies are necessary to ultimately understand the clinical implications of these findings and further guide the proper use of these medications or identify safer alternatives.
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